FDA Expands Recall Of Blood Pressure Drugs Again

(CNN) — Torrent Pharmaceuticals Ltd. has expanded its voluntary recall of two blood pressure medications after trace amounts of a potentially cancer-causing impurity were found during testing. The recall affects Losartan Potassium Tablets USP and Losartan Potassium/hydrochlorothiazide tablets. Tests of some of those medications revealed amounts of N-methylnitrosobutyric acid (NMBA) that were above the US Food and Drug Administration’s daily acceptable levels. This recall is related to the valsartan recall that has been expanded multiple times since July, when separate lots of blood pressure medications from different companies began being pulled from pharmacy shelves. The medications all contained either valsartan, losartan or irbesartan and had traces of these impurities that pose a cancer risk to users. The FDA has begun testing all heart drugs called angiotensin II receptor blockers for these impurities. Also known as ARBs, they block a potent chemical in the blood called angiotensin that causes muscles surrounding blood vessels to contract. When the chemical binds, it narrows the vessels, and that can cause high blood pressure. What this recall includes This current expansion includes three additional lots of Losartan Potassium Tablets USP and two lots of Losartan Potassium/Hydrochlorothiazide Tablets, USP. Patients currently taking the medication should continue doing so “as the risk of harm to the patient’s health may be higher if the treatment i...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News Syndicated CBSN Boston CNN Recall Valsartan Source Type: news

Related Links:

Rationale: Anlotinib has been proved to be effective in advanced refractory non-small cell lung cancer. Patient concerns: A 47-year-old female non-smoker was admitted due to persistent chest tightness for a month. Diagnoses: Epidermal growth factor receptor (EGFR) wild-type advanced primary lung adenocarcinoma without brain or bone metastasis. Interventions: The patient failed 2 lines of pemetrexed/docetaxel plus carboplatin and third-line erlotinib. Fourth-line anlotinib was administered thereafter. Outcomes: The pulmonary lesions showed partial remission 5 months after anlotinib monotherapy. The patient dem...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
AbstractPurposeDiabetic ’s patients are supposed to experience higher rates of COVID-19 related poor outcomes. We aimed to determine factors predicting poor outcomes in hospitalized diabetic patients with COVID-19.MethodsThis retrospective cohort study included all adult diabetic patients with radiological or laboratory confirmed COVID-19 who hospitalized between 20 February 2020 and 27 April 2020 in Alborz province, Iran. Data on demographic, medical history, and laboratory test at presentation were obtained from electronic medical records. Diagnosis of diabetes mellitus was self-reported. Comorbidities including ca...
Source: Journal of Diabetes and Metabolic Disorders - Category: Endocrinology Source Type: research
(Penn State) A large, international study of COVID-19 patients confirmed that cardiovascular disease, hypertension, diabetes, congestive heart failure, chronic kidney disease, stroke and cancer can increase a patient's risk of dying from the virus.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
AbstractVitamin C (Vit C) is an ideal antioxidant as it is easily available, water soluble, very potent, least toxic, regenerates other antioxidants particularly Vit E, and acts as a cofactor for different enzymes. It has received much attention due to its ability in limiting reactive oxygen species, oxidative stress, and nitrosative stress, as well as it helps to maintain some of the normal metabolic functions of the cell. However, over 140 clinical trials using Vit C in different pathological conditions such as myocardial infarction, gastritis, diabetes, hypertension, stroke, and cancer have yielded inconsistent results....
Source: Heart Failure Reviews - Category: Cardiology Source Type: research
This study sought to analyze the impact of oral and mental health on the quality of life of older people enrolled in a Family Health Unit, as well as its associated factors. Methods This was a cross-sectional, descriptive, exploratory study, conducted through interviews. The probabilistic sample consisted of 86 older people, users of the unit, aged 60 and over, dependent or independent, from both sexes. The methodological frameworks adopted for data collection were the evaluation of oral health conditions (edentulism) and the structured interview, employing oral health perception questionnaires (SB-Brazil), the OHIP &ndash...
Source: RGO - Revista Gaucha de Odontologia - Category: Dentistry Source Type: research
CONCLUSIONS: Our results indicate that, by overexpressing NUDT1, PAH-PASMCs hijack persistent oxidative stress in preventing incorporation of oxidized nucleotides into DNA, thus allowing the cell to escape apoptosis and proliferate. Given that NUDT1 inhibitors are under clinical investigation for cancer, they may represent a new therapeutic option for PAH. PMID: 33021405 [PubMed - as supplied by publisher]
Source: Am J Respir Crit Car... - Category: Intensive Care Authors: Tags: Am J Respir Crit Care Med Source Type: research
Purpose of review With the aging population of kidney transplant candidates, a history of malignancy is an increasingly prevalent finding. Tumors can constitute a contraindication for transplantation or can lead to a delay of acceptance to the waiting-list. Current waiting time guidelines mainly refer to early data collected nearly 30 years ago, when the knowledge on tumors was, by current standards, still limited. Recent findings Today, cancers can usually be divided into many different biological subtypes, according to histological and molecular subclassification and the availability of genetic testing. A more preci...
Source: Current Opinion in Nephrology and Hypertension - Category: Urology & Nephrology Tags: DIALYSIS AND TRANSPLANTATION: Edited by David J. Cohen Source Type: research
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
[Monitor] It is common knowledge that people living with non-communicable diseases (NCDs) such as hypertension, cancer, diabetes, and chronic respiratory disease, are more vulnerable to catching a severe form of Covid-19, and dying.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Glob...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Avalide | Avapro | Cancer | Cancer & Oncology | Cardiology | Chemistry | Contracts | Cozaar | Diovan | Food and Drug Administration (FDA) | Health | Heart | Hydrochlorothiazide | Hypertension | Losartan | Potassium | Sports Medicine